Kiora Pharmaceuticals price target lowered to $2 from $3.50 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Kiora Pharmaceuticals to $2 from $3.50 and keeps a Buy rating on the shares. The analyst believes the partnership should provide Kiora with sufficient capital to complete the Phase 2 trial of KIO-301.